- PR Newswire•24 minutes ago
Allergan Granted Marketing Authorization by the FDA for TrueTear™, the First Intranasal Neurostimulating Device Proven to Temporarily Increase Tear Production
DUBLIN, April 25, 2017 /PRNewswire/ -- Allergan plc, (NYSE: AGN) today announced that it has been granted marketing authorization from the U.S. Food and Drug Administration (FDA) for TrueTear ™ Intranasal ...
- Reuters•18 hours ago
Large drugmakers with piles of cash are on the hunt for promising medicines being developed by small companies to treat NASH, a progressive fatty liver disease poised to become the leading cause of liver ...
- TheStreet.com•19 hours ago
The Trump administration's executive order on tax regulations could revive the defunct Allergan-Pfizer merger.
AGN : Summary for Allergan plc Ordinary Shares - Yahoo Finance
Allergan plc (AGN)
NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
|Bid||235.53 x 200|
|Ask||238.00 x 500|
|Day's Range||236.69 - 238.63|
|52 Week Range||184.50 - 261.27|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||6.21|
|Dividend & Yield||2.80 (1.19%)|
|1y Target Est||N/A|